Lanying Du - Search Results

Year	Number of Results
2005	1
2006	4
2007	2
2008	4
2009	3
2010	9
2011	4
2012	8
2013	17
2014	19
2015	22
2016	11
2017	12
2018	9
2019	10
2020	24
2021	10
2022	5

1

The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. Du L, et al. Nat Rev Microbiol. 2009 Mar;7(3):226-36. doi: 10.1038/nrmicro2090. Epub 2009 Feb 9. Nat Rev Microbiol. 2009. PMID: 19198616 Free PMC article. Review.

2

Learning from the past: development of safe and effective COVID-19 vaccines.

Su S, Du L, Jiang S. Su S, et al. Among authors: du l. Nat Rev Microbiol. 2021 Mar;19(3):211-219. doi: 10.1038/s41579-020-00462-y. Epub 2020 Oct 16. Nat Rev Microbiol. 2021. PMID: 33067570 Free PMC article.

3

Recent advances in the detection of respiratory virus infection in humans.

Zhang N, Wang L, Deng X, Liang R, Su M, He C, Hu L, Su Y, Ren J, Yu F, Du L, Jiang S. Zhang N, et al. Among authors: du l. J Med Virol. 2020 Apr;92(4):408-417. doi: 10.1002/jmv.25674. Epub 2020 Feb 4. J Med Virol. 2020. PMID: 31944312 Free PMC article. Review.

4

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.

Jiang S, Hillyer C, Du L. Jiang S, et al. Among authors: du l. Trends Immunol. 2020 May;41(5):355-359. doi: 10.1016/j.it.2020.03.007. Epub 2020 Apr 2. Trends Immunol. 2020. PMID: 32249063 Free PMC article.

5

Neutralizing antibodies for the prevention and treatment of COVID-19.

Du L, Yang Y, Zhang X. Du L, et al. Cell Mol Immunol. 2021 Oct;18(10):2293-2306. doi: 10.1038/s41423-021-00752-2. Epub 2021 Sep 8. Cell Mol Immunol. 2021. PMID: 34497376 Free PMC article. Review.

6

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.

Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou Y, Du L, Li F. Wan Y, et al. Among authors: du l. J Virol. 2020 Feb 14;94(5):e02015-19. doi: 10.1128/JVI.02015-19. Print 2020 Feb 14. J Virol. 2020. PMID: 31826992 Free PMC article.

7

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L. Xia S, et al. Among authors: du l. Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. Epub 2020 Mar 30. Cell Res. 2020. PMID: 32231345 Free PMC article.

8

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.

Tai W, Zhang X, Drelich A, Shi J, Hsu JC, Luchsinger L, Hillyer CD, Tseng CK, Jiang S, Du L. Tai W, et al. Among authors: du l. Cell Res. 2020 Oct;30(10):932-935. doi: 10.1038/s41422-020-0387-5. Epub 2020 Aug 5. Cell Res. 2020. PMID: 32759966 Free PMC article. No abstract available.

9

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.

Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L. Xia S, et al. Among authors: du l. Sci Adv. 2019 Apr 10;5(4):eaav4580. doi: 10.1126/sciadv.aav4580. eCollection 2019 Apr. Sci Adv. 2019. PMID: 30989115 Free PMC article.

10

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Tai W, et al. Among authors: du l. Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19. Cell Mol Immunol. 2020. PMID: 32203189 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results